Aptevo expects to start IND-enabling studies for lead candidate APVO451 in H1 2027

Aptevo Therapeutics says it expects to enter investigational new drug (IND)-enabling studies for its lead candidate APVO451 in the first half of 2027.

Detected & updated continuously · Source: Nebula